SAB Biotherapeutics (SABS) Appoints Jay Skyler to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to SAB Biotherapeutics (SABS) Appoints Jay Skyler to its Board

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

May 6, 2024 7:15 AM EDT

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the Company or SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the companys Board of Directors.

Dr. Skylers appointment to our Board of Directors is a major milestone for SAB, said Samuel J. Reich, SABs chairman and Chief Executive Officer. His deep expertise in type 1 diabetes research and leadership in the... More